SHR-1701 in Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma

NCT04282070 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

91

Enrollment

INDUSTRY

Sponsor class

Conditions

Nasopharyngeal Carcinoma

Interventions

DRUG: SHR-1701
DRUG: Gemcitabine
DRUG: Cisplatin
DRUG: Albumin Paclitaxel

Sponsor

Jiangsu HengRui Medicine Co., Ltd.